{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=3&state=Oregon", "query": { "state": "Oregon", "city": "Portland", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 9360, "total_pages": 936, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=4&state=Oregon&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=2&state=Oregon&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T19:35:26.943Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05685004", "title": "Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma Multiforme of Brain" ], "interventions": [ { "name": "TVI-Brain-1", "type": "BIOLOGICAL" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "TVAX Biomedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 120, "start_date": "2023-12-27", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05685004" }, { "nct_id": "NCT01909752", "title": "Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "DRibble vaccine", "type": "BIOLOGICAL" }, { "name": "Imiquimod", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "HPV vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "UbiVac", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-07", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 2, "location_summary": "New Orleans, Louisiana • Portland, Oregon", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909752" }, { "nct_id": "NCT03980730", "title": "Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Azeliragon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "vTv Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 43, "start_date": "2019-06-27", "completion_date": "2021-01-29", "has_results": true, "last_update_posted_date": "2022-01-21", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 27, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03980730" }, { "nct_id": "NCT00137436", "title": "Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "SU011248", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 93, "start_date": "2005-10", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-08-29", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 24, "location_summary": "Harvey, Illinois • Tinley Park, Illinois • Hobart, Indiana + 17 more", "locations": [ { "city": "Harvey", "state": "Illinois" }, { "city": "Tinley Park", "state": "Illinois" }, { "city": "Hobart", "state": "Indiana" }, { "city": "Munster", "state": "Indiana" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137436" }, { "nct_id": "NCT01302587", "title": "A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Asthma", "Chronic Obstructive Pulmonary Disease (COPD)", "Emphysema", "Chronic Bronchitis" ], "interventions": [ { "name": "Albuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 306, "start_date": "2011-03", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2012-06-22", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 25, "location_summary": "Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01302587" }, { "nct_id": "NCT02923193", "title": "Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Shockwave Lithoplasty® Peripheral Lithoplasty System", "type": "DEVICE" }, { "name": "Medtronic IN.PACT (DCB)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Shockwave Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2017-02-22", "completion_date": "2022-06-02", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 40, "location_summary": "Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 33 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Loveland", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02923193" }, { "nct_id": "NCT00053833", "title": "S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 2, "start_date": "2003-04", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2013-11-08", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 99, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053833" }, { "nct_id": "NCT04279236", "title": "Multi-Center Study on Performance of the Ponto Implant System Using Minimally Invasive Ponto Surgery (in Adult Patients)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hearing Loss" ], "interventions": [ { "name": "Abbreviated Profile Hearing Aid Benefit (APHAB)", "type": "OTHER" }, { "name": "Glasgow Benefit Inventory (GBI)", "type": "OTHER" }, { "name": "Additional follow-up visit", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Oticon Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2020-06-15", "completion_date": "2024-12-10", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 6, "location_summary": "Sarasota, Florida • Indianapolis, Indiana • New York, New York + 3 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04279236" }, { "nct_id": "NCT03036098", "title": "Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1314, "start_date": "2017-03-24", "completion_date": "2026-05-15", "has_results": true, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fresno", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03036098" }, { "nct_id": "NCT01722487", "title": "Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 269, "start_date": "2013-03", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-10-30T19:35:26.943Z", "location_count": 22, "location_summary": "Duarte, California • La Jolla, California • Santa Rosa, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01722487" } ] }